Abstract
The Fergana Valley model was used to study the risk of postcovid interstitial lung disease in patients who have had COVID-19 associated pneumonia with 50% or more of the pulmonary parenchyma affected. Predictors of the formation of postcovid pulmonary fibrosis were determined and a risk assessment scale was developed. It was found that the use of ultrasound scanners in the early postcovid period is informative and is not inferior in terms of predicting fibrosis by serial MSCT.
Highlights
COVID-19 has acquired a pandemic character due to extremely high contagiousness
A follow-up study by Zhao et al [8,9,10,11] of pulmonary function and radiology in 55 patients who survived COVID-19 3 months after recovery showed that 71% had residual CT abnormalities, including evidence of interstitial thickening in 27%
Saturation in the patients included in the study was significantly reduced, both in comparison with the conditional norm (93%) and in comparison with the control group (CG) (84.90 ± 0.80% versus 97.20 ± 0.21%, p
Summary
COVID-19 has acquired a pandemic character due to extremely high contagiousness. The social significance of the disease is increasing, in addition to its widespread prevalence, extremely high mortality and a high incidence of life-threatening complications, such as severe pneumonia (10% of patients), acute respiratory distress syndrome in adults (5%) and thrombotic complications. A study of survivors from the COVID-19 pandemic in Italy found that up to 45% still complained of shortness of breath during follow-up visits, an average of 60 days (standard deviation 13.6 days) after the symptom first appeared. A follow-up study by Zhao et al [8,9,10,11] of pulmonary function and radiology in 55 patients who survived COVID-19 3 months after recovery showed that 71% had residual CT abnormalities, including evidence of interstitial thickening in 27%. Survivors, 83% showed signs of progression with opacification, interstitial thickening and fibrous streaks. Cells and reconstruction similar to those found in idiopathic pulmonary fibrosis were seen
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The American Journal of Medical Sciences and Pharmaceutical Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
